Novo Nordisk Shares Rise After Positive Oral Semaglutide Trial In Children

All NewsApril 24, 2026

Novo Nordisk shares are up on Friday after reporting oral semaglutide trial results in children aged 10-17 years old with type 2 diabetes.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent